

✓
GAU 1632
\$
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Pat nt Examining Operations



27162

PATENT TRADEMARK OFFICE

Applicant(s): Hallenbeck, et al.

Serial No: 09/373,938

Filed: August 13, 1999

Title: Adenoviral Vectors Including DNA Sequences Encoding Angiogenic Inhibitors

Art Unit: 1632

Examiner: Brunovskis

Attorney

Docket No.: 271010-445

Customer No. 27162

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

RECEIVED

MAR 15 2001

Enclosed please find the following:

TECH CENTER 1600/2900

1. Information Disclosure Statement;
2. Form PTO-1449, including references;
3. A check in the amount of \$180.00; and
4. A self-addressed, postage paid, return receipt postcard, date stamp and return of which is respectfully requested.

The Commissioner is authorized to charge payment of any additional filing fees required under 37 C.F.R. 1.16 associated with this communication or credit any overpayment to Deposit **Account No. 03-0678**.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

Raymond J. Lillie 3/6/01
Raymond J. Lillie, Esq. Date

Respectfully submitted,

Raymond J. Lillie

Raymond J. Lillie, Esq.
Reg. No. 31,778

CARELLA, BYRNE, BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, New Jersey 07068
T: (973) 994-1700
F: (973) 994-1744

#12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF: Hallenbeck, et al.

SERIAL NO: 09/373,938


GROUP ART UNIT: 1632

FILED: August 13, 1999

EXAMINER: Brunovskis

FOR: Adenoviral Vectors Including DNA Sequences Encoding Angiogenic Inhibitors

CUSTOMER NO.: 27162



RECEIVED

MAR 15 2001

TECH CENTER 1600/2900

Commissioner of Patents and Trademarks
Washington, DC 20231

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

- ☐ §1.97(b) This Information Disclosure Statement is filed:
- (1) Within three months of the filing date of a national application; OR
 - (2) Within three months of the date of entry of the national stage of an international application; OR
 - (3) Before the mailing of a first Office Action on the merits.
No fee or statement is required.

- ☐ §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:
- (1) A Final Action or under 37 CFR §1.113; OR
 - (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

- ☐ The statement as specified in 37 CFR §1.97(e) set out below; OR
☐ The fee of \$180.00 under 37 CFR §1.17(p).

- ☒ §1.97(d) This Information Disclosure Statement is filed after the mailing date of either:
- (1) a Final Action or under 37 CFR §1.113; OR
 - (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below;
AND

- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$180.00 set out in 37 CFR §1.17(i).


X §1.97(e) The undersigned Attorney hereby states that:

X each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;

or


— no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE	
I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:	
Commissioner for Patents Washington, DC 20231	
 Raymond J. Lillie, Esq.	<u>3/6/01</u> Date

#96946 v1

Respectfully submitted,


Raymond J. Lillie, Esq.

Reg. No. 31,778

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN

Six Becker Farm Road

Roseland, NJ 07068

Tel: (973) 994-1700

Fax: (973) 994-1744